Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Is air travel safe for those with lung disease?

E. Marchand
European Respiratory Journal 2008 31: 1137-1138; DOI: 10.1183/09031936.00175407
E. Marchand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

I read with interest the article of Coker et al. 1 regarding the safety of commercial air travel for patients with lung disease. This is an area of concern since both the prevalence of chronic obstructive pulmonary disease and the number of people flying for leisure purposes are increasing. The available guidelines are based on very limited scientific evidence. Owing to the lack of data and potential adverse consequences of hypoxaemia induced by air travel, the recommendations proposed by scientific societies and panel guidelines are purposefully cautious.

The prospective evaluation of a large cohort such as the one described by Coker et al. 1 is of great value for increasing knowledge in this field, and potentially for the refinement of recommendations for patients planning air travel. If patients included in the study of Coker et al. 1 were indeed managed according to guidelines, it can be concluded that these guidelines are appropriate for predicting safe air travel. It could be argued, however, that current guidelines are too restrictive or cautious. The guidelines all recommend avoidance of hypoxaemia below an arterial oxygen tension (Pa,O2) of 6.7 kPa (50 mmHg) 2–4 or 7.3 kPa (55 mmHg) 2, 5.

Bearing this in mind, it would be of great value to the scientific community to obtain the following additional information, which is probably already available to Coker et al. 1. 1) How many patients with an arterial oxygen saturation measured by pulse oximetry (Sp,O2) of 92–95% underwent hypoxic challenge testing (HCT)? 2) Did all patients with a Pa,O2 of 6.7 kPa (50 mmHg) during HCT fly with oxygen? 3) How many patients with an Sp,O2 of <92% at ground level flew without oxygen?

HCT is useful for predicting the level of hypoxaemia that patients will experience during a flight. However, it is not clear which patients should undergo HCT, i.e. which patients are at risk of an in-flight Pa,O2 of <6.7 kPa (<50 mmHg). Coker et al. 1 reported that 19 of the 82 patients who underwent hypoxic challenge testing despite a ground-level Sp,O2 of ≥96% did indeed experience severe hypoxaemia during the test. It would be interesting to characterise these patients. How do they compare to those of the same ground-level Sp,O2 but without severe hypoxaemia under hypoxic conditions? Limited data from the literature suggest that patients with very severe obstructive lung disease (forced expiratory volume in one second of <1 L 6 and/or hypercapnia 7, 8) are at risk of severe in-flight hypoxaemia despite a good ground-level Sp,O2.

Accordingly, it would also be interesting to have answers to the following questions concerning Global Initiative for Chronic Obstructive Lung Disease stage IV chronic obstructive pulmonary disease patients. 1) How many patients with a ground-level arterial oxygen saturation measured by pulse oximetry of >95% underwent hypoxic challenge testing? 2) How many patients flew without oxygen and without pre-flight hypoxic challenge testing?

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Coker RK, Shiner RJ, Partridge MR. Is air travel safe for those with lung disease?. Eur Respir J 2007;30:1057–1063.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      British Thoracic Society Standards of Care Committee. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2002;57:289–304.
      OpenUrlFREE Full Text
    3. American Thoracic Society, European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. www.thoracic.org/sections/copd/resources/copddoc.pdf. Date last updated: November 30, 2006. Date last accessed: December 26, 2007
    4. ↵
      Marchand E, Chavaillon JM, Duguet A. Quels sont les patients chez lesquels le voyage aérien comporte un risque d’insuffisance respiratoire? [Who are the patients for whom air travel comprises a risk of respiratory insufficiency?]. Rev Mal Respir 2007;24:4S42–4S52.
      OpenUrlPubMed
    5. ↵
      Medical guidelines for air travel. Aerospace Medical Association, Air Transport Medicine Committee, Alexandria, Va. Aviat Space Environ Med 1996;67: Suppl. 10 B1–B16.
      OpenUrlPubMed
    6. ↵
      Dillard TA, Berg BW, Rajagopal KR, Dooley JW, Mehm WJ. Hypoxemia during air travel in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989;111:362–367.
      OpenUrlPubMedWeb of Science
    7. ↵
      Dillard TA, Moores LK, Bilello KL, Phillips YY. The preflight evaluation. A comparison of the hypoxia inhalation test with hypobaric exposure. Chest 1995;107:352–357.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Christensen CC, Ryg M, Refvem OK, Skjønsberg OH. Development of severe hypoxaemia in chronic obstructive pulmonary disease patients at 2,438 m (8,000 ft) altitude. Eur Respir J 2000;15:635–639.
      OpenUrlAbstract
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 31 Issue 5 Table of Contents
    European Respiratory Journal: 31 (5)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Is air travel safe for those with lung disease?
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Is air travel safe for those with lung disease?
    E. Marchand
    European Respiratory Journal May 2008, 31 (5) 1137-1138; DOI: 10.1183/09031936.00175407

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Is air travel safe for those with lung disease?
    E. Marchand
    European Respiratory Journal May 2008, 31 (5) 1137-1138; DOI: 10.1183/09031936.00175407
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Treatable traits approach in interstitial lung disease
    • Reply: Treatable traits approach in interstitial lung disease
    • Reply: TB screening in migrants to the EU/EEA and UK
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society